Ahmed Magdy Rabea, Assistant Professor at National Cancer Institute, shared a post on LinkedIn:
“It was my pleasure to give a comprehensive talk about the AEGEAN trial using Durvalumab in the perioperative setting in NSCLC during the prestigious ISCO meeting 2025. Thank you AstraZeneca for inviting me to be your speaker.”
